Market Research Report
Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||928276|
|Published||Content info||111 Pages
Delivery time: 1-2 business days
|Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030|
|Published: March 1, 2020||Content info: 111 Pages||
DelveInsight's 'Chronic Hand Eczema (CHE)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the CHE, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Chronic Hand Eczema (CHE) Disease Understanding
Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder exclusively localized to the hands. It is a highly prevalent, multi-etiological disease with a wide spectrum of severity and chronicity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance potentially damaging allergens and/or irritants.
Chronic Hand Eczema (CHE) has been defined as a long-lasting, relapsing course of Hand Eczema that is
CHE as an anatomoclinic syndrome with multifactorial origins that is not restricted to allergic or orthoergic origin. Clinical features include localization of eczema to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/blistering, fissures, pruritus, and pain. It is typically a dynamic condition extending over the years, and its morphology may change with time, both clinically and histologically. Erythema, edema, and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis, and fissures are seen in chronic eczema. It has significant morbidity and lost earnings and has severe negative impacts on the social and psychosocial aspects of patients' lives.
The CHE epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The total diagnosed prevalent cases of Chronic Hand Eczema (CHE) patients 7MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted CHE symptoms epidemiology segmented as the Total prevalence of CHE, Gender-Specific cases of CHE, Diagnosed cases of CHE, Age-Specific cases of CHE, Severity Specific Cases of CHE and Subgroup Specific Cases of CHE. The report includes the prevalent scenario of CHE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017-2030.
The epidemiology segment also provides the Chronic Hand Eczema (CHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
According to DelveInsight, The total prevalent population of CHE Associated in 7MM countries ranges from 4,229,215 in 2017.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
The Chronic Hand Eczema (CHE) Epidemiology report will allow the user to -
Study Period: 2017-2030
As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. The same number of estimation is found in the Thyssen et al., (2010) and others. Chronic Hand Eczema is estimated to occur in 5-7% of patients with Hand Eczema. As per Diepgen et al., Severe chronic HE has a major adverse impact on economic and social functions, with although abundant treatment options but with limited efficacy.
The chronic hand eczema registry on long-term patient management (CARPE) registry is the worldwide first registry of CHE that has been initiated in Germany which has a great contribution to health care research of chronic hand eczema. The CARPE was initiated in 2009, with the aim to investigate characteristics and treatment modalities in patients affected by chronic hand eczema in Germany. CARPE Registry-2015 found that mean disease duration was almost 8 years and CHE was graded as very severe or severe in approximately 70% of affected patients. Overall, 41% of patients had an atopic background and a type IV sensitization was reported in 48% of patients. Atopic hand eczema and allergic contact dermatitis were, however, reported in 34% and 22%.
Currently, register on patients with chronic hand eczema data from CARPE and a Swiss "sister-registry" showed that a significant proportion of patients may not receive adequate treatment according to guidelines. Future research will need to make use of longitudinal data to study the course of the disease and the effectiveness of different therapies in a comparative manner